IMMUNO-ONCOLOGY INSIGHTS

Hunting for better biomarkers of response

June 2021

  • CTLA-4 expression by human tumor cells and its impact on immunotherapeutic strategies: a systematic review

    F Abdulkhaleq,
    Farah Abdulkhaleq
    Equally contributing first author Institute of Medical Sciences, University of Aberdeen, UK
    N Larossi,
    Niss Larossi
    Equally contributing first author Institute of Medical Sciences, University of Aberdeen, UK and Institute of Biological Sciences, University of Manchester, UK
    O Ogbonda et al.
    Okanda Ogbonda
    Equally contributing first author Institute of Medical Sciences, University of Aberdeen, UK
    23 June 2021
    Review
  • Leveraging the advantages of liquid biopsy for predictive and prognostic biomarkers in R&D

    C Punyadeera
    Chamindie Punyadeera
    Associate Professor, Queensland University of Technology chamindie.punyadeera@qut.edu.au
    14 June 2021
    Viewpoint
  • Hunting for better biomarkers of response: where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?

    A Daud,
    Dr Adil Daud
    Professor of Medicine and Dermatology, University of California; and Director of the Melanoma program, Helen Diller Family Cancer Center, UCSF
    S Fling,
    Steven Fling, PhD
    Senior Staff Scientist, Fred Hutchinson Cancer Research Center; and Lab Director, Central Immune Monitoring Lab
    J Rossi et al.
    John Rossi
    Senior Director, Department of Translational Medicine, Kite
    9 June 2021
    Expert Roundtable Video
  • Hunting for better biomarkers of response: where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?

    A Daud,
    Dr Adil Daud
    Professor of Medicine and Dermatology, University of California; and Director of the Melanoma program, Helen Diller Family Cancer Center, UCSF
    S Fling,
    Steven Fling, PhD
    Senior Staff Scientist, Fred Hutchinson Cancer Research Center; and Lab Director, Central Immune Monitoring Lab
    J Rossi et al.
    John Rossi
    Senior Director, Department of Translational Medicine, Kite
    9 June 2021
    Expert Roundtable
  • Digital pathology for the identification of prognostic biomarkers in head and neck cancer

    R Abu-Eid,
    Rasha Abu-Eid
    Author for correspondence: Institute of Dentistry, University of Aberdeen, UK and Institute of Medical Sciences, University of Aberdeen, UK rasha.abueid@abdn.ac.uk
    F Ward
    Frank James Ward
    Institute of Medical Sciences, University of Aberdeen, UK
    8 June 2021
    Expert Insight
  • Driving the development of microbiome-based biomarkers of patient response to immunotherapy

    R Fernandes,
    Ricardo Fernandes
    Medical Oncologist, London Regional Cancer Program and Assistant Professor, The Department of Oncology, Western University
    J Lenehan,
    John Lenehan
    Medical Oncologist, London Regional Cancer Program and Assistant Professor, Department of Oncology, Western University and Adjunct Scientist, Lawson Health Research Institute.
    S Maleki
    Saman Maleki
    Assistant Professor, Departments of Oncology, Pathology and Laboratory Medicine, and Medical Biophysics, Western University and Scientist, London Regional Cancer Program, Lawson Health Research Institute
    8 June 2021
    Interview
  • Reflecting on Merck’s I-O biomarker development journey

    E Rubin
    Eric H Rubin, MD
    SVP & Therapeutic Area Head, Oncology Early Development, Merck Research Laboratories
    Eric H Rubin has focused on cancer drug development for over 25 years, initially as a faculty member at the DanaFarber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey, where he served as the Director of the Investigational Therapeutics Division of that institution. His research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs and his laboratory cloned TOPORS, a novel topoisomerase I- and p53-interacting tumor suppressor gene. In 2008 he was recruited to Merck to lead the clinical oncology development team. Under his leadership, the clinical oncology group underwent a transformational change in an effort to realize the potential of cancer immunotherapy. He led the initial development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the USA, and in the identification of the significant activity of this breakthrough therapeutic across several cancer types. In 2014 Dr. Rubin was asked to head up Oncology Early Development for Merck, and in this role he oversees development of a promising and expansive early pipeline, as well as translational oncology research activities. Dr. Rubin has authored over 100 original, peer-reviewed publications and book chapters related to oncology translational research, clinical trials, and drug development. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology. He is a co-chair of the Cancer Steering Committee of the Biomarkers Consortium, Foundation of the National Institute of Health, a member of the Science Policy and Governmental Affairs Committee for AACR, and was a member of the National Cancer Moonshot Initiative/Blue Ribbon Panel Working Group on Expanding Clinical Trials.
    8 June 2021
    Interview